Detalhe da pesquisa
1.
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Eur J Haematol
; 105(1): 35-46, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32145111
2.
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Blood
; 130(24): 2610-2618, 2017 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29054911
3.
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Br J Haematol
; 178(4): 571-582, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28485007
4.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Br J Haematol
; 178(4): 547-560, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28466536
5.
The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.
Br J Haematol
; 174(3): 368-81, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27265837
6.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Blood
; 124(16): 2498-506, 2014 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-25202139
7.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Blood
; 123(5): 632-9, 2014 Jan 30.
Artigo
Inglês
| MEDLINE | ID: mdl-24335104
8.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood
; 123(10): 1461-9, 2014 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-24429336
9.
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol
; 95(12): 2033-2041, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27738789
10.
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Br J Clin Pharmacol
; 79(5): 789-800, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25377318
11.
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Br J Haematol
; 166(6): 920-8, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25039282
12.
Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Blood
; 120(23): 4513-6, 2012 Nov 29.
Artigo
Inglês
| MEDLINE | ID: mdl-23018640
13.
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Haematologica
; 99(6): 1114-22, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24763402
14.
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Blood
; 118(4): 865-73, 2011 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-21562045
15.
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood
; 118(3): 535-43, 2011 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-21596852
16.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artigo
Inglês
| MEDLINE | ID: mdl-20628153
17.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood
; 116(5): 679-86, 2010 Aug 05.
Artigo
Inglês
| MEDLINE | ID: mdl-20385792
18.
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Eur J Haematol
; 89(1): 16-27, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22469559
19.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Lancet Oncol
; 12(8): 773-84, 2011 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-21724462
20.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21507715